Application of PBPK modeling to predict monoclonal antibody disposition in plasma and tissues in mouse models of human colorectal cancer

Pharmacokinetic mAb–mAb Interaction: Anti-VEGF mAb Decreases the Distribution of Anti-CEA mAb into Colorectal Tumor Xenografts

(2012) Lubna Abuqayyas et al.   AAPS Journal

Effects of Anti-VEGF on Pharmacokinetics, Biodistribution, and Tumor Penetration of Trastuzumab in a Preclinical Breast Cancer Model

(2012) C. V. Pastuskovas et al.   MOLECULAR CANCER THERAPEUTICS

Towards a platform PBPK model to characterize the plasma and tissue disposition of monoclonal antibodies in preclinical species and human

(2011) Dhaval K. Shah et al.   JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS

Effects of Anti-VEGF on Predicted Antibody Biodistribution: Roles of Vascular Volume, Interstitial Volume, and Blood Flow

(2011) C. Andrew Boswell et al.   PLoS One

Physiologically based pharmacokinetic model for T84.66: A monoclonal anti-CEA antibody

(2009) Shweta R. Urva et al.   JOURNAL OF PHARMACEUTICAL SCIENCES

Use of an Anti-Vascular Endothelial Growth Factor Antibody in a Pharmacokinetic Strategy to Increase the Efficacy of Intraperitoneal Chemotherapy

(2009) D. K. Shah et al.   JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS

Kinetics of anti-carcinoembryonic antigen antibody internalization: effects of affinity, bivalency, and stability

(2008) Michael M. Schmidt et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Antibody-Based Therapy for Solid Tumors

(2008) Li Yan et al.   CANCER JOURNAL

Quantitative Spatiotemporal Analysis of Antibody Fragment Diffusion and Endocytic Consumption in Tumor Spheroids

(2008) G. M. Thurber et al.   CANCER RESEARCH

Effect of antigen turnover rate and expression level on antibody penetration into tumor spheroids

(2008) M. E. Ackerman et al.   MOLECULAR CANCER THERAPEUTICS

A physiologically based pharmacokinetic (PBPK) model to characterize and predict the disposition of monoclonal antibody CC49 and its single chain Fv constructs

(2007) Jasmine P. Davda et al.   INTERNATIONAL IMMUNOPHARMACOLOGY